Curasight A/S (CPH:CURAS), a Denmark-based clinical-stage radiopharmaceutical company, announced on Tuesday that it will present recent company progress, including the ongoing Phase 1 clinical trial uTREAT in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on 3 March 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight's management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is an investor conference where public and private healthcare companies meet with institutional investors and large pharma via scheduled 1:1 meetings and presentations combined with fireside chats and panel discussions.

Curasight is advancing uTREAT, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumours. uTREAT targets uPAR, a key driver of tumour invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumours.